Skye Bioscience Inc. (SKYE): שווי פעילות לרווח לפני ריבית, מסים ופחת
Skye Bioscience, Inc. (SKYE) develops cannabinoid-based medicines, leveraging university partnerships to accelerate testing for anti-obesity treatments. The company is establishing a biotechnology hub by introducing innovations in glaucoma therapy. This price chart reflects an EV/EBITDA ratio of 0.00. Management has successfully realigned the research portfolio to match current market trends while maintaining shareholder confidence.
פילוחי מדדים ואנליטיקה של חברת Skye Bioscience Inc. (SKYE)
When screening issuer reliability, it is critical to evaluate business value relative to operating profit. The EV/EBITDA indicator aggregates market capitalization and net debt, dividing them by earnings before interest, taxes, depreciation, and amortization to determine the asset's real value. For Skye Bioscience, Inc. (SKYE), with its liquid balance sheet and biopharmaceutical developments, this metric confirms capital stability. By analyzing the current EV/EBITDA value of Skye Bioscience, Inc. (SKYE), an investor determines whether the market price is fair relative to growth rates.
